Development of 5-(3-alkenyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine derivatives as selective muscarinic agonists for the treatment of Alzheimer's disease von Zhang, H., Ojo, B., Huang, X.-P., Edgar, M.A.N., El-Assadi, A.A., Baril, D., Lynch, K., Wahidy, S., Nagy, P.I., Messer, W.S.

Volltext